Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,630 total articles
CervoMed Inc., a clinical-stage biotech developing treatments for age-related brain disorders, announced management's participation in major September investor conferences. The company highlighted its lead drug candidate neflamapimod's progress, including a completed Phase 2b trial in dementia with Lewy bodies (DLB), discussions with the FDA on reg…
Artiva Biotherapeutics announced plans to initiate a Phase 3 registrational trial in refractory rheumatoid arthritis (RA) during the second half of 2026, alongside updated clinical data disclosures from their ongoing Phase 2a basket trial in RA, Sjögren disease, and systemic sclerosis. The company expects to present data from at least 20 RA patient…
Pyxis Oncology has appointed Thomas Civik as its Chief Executive Officer and Chairman of the Board, marking a leadership transition as the company advances key clinical milestones for its lead candidate MICVO, a novel antibody-drug conjugate for difficult-to-treat cancers. Civik brings significant industry experience, previously leading successful …
United Community Banks has finalized key strategic initiatives including the sale of Navitas Credit Corp., a significant repositioning of its investment securities portfolio to reduce interest rate risk and improve earnings, and an increased share repurchase authorization of $100 million through 2027. The company is focusing on organic loan growth,…
Edible Garden AG Incorporated announced its participation in ECRM's Vitamin, Weight Management & Sports Nutrition Session in September 2026, where it will highlight its Kick. Sports Nutrition line and expanding private-label ready-to-drink (RTD) products. The company aims to leverage these opportunities to expand distribution and scale its nutritio…
ASML Holding N.V. commenced construction of its second major industrial campus at Brainport Industries Campus North in Eindhoven, the Netherlands. The new facility, set to open its first phase by 2029, will support ASML's growth by providing advanced manufacturing capacity and workspace for 3,000 employees initially, with long-term scalability up t…
Polar Power, Inc. has successfully reduced its outstanding Pinnacle Bank debt by approximately $3 million, lowering the balance from $4.7 million to about $1.667 million as of September 2026. The company expects to fully repay the remaining balance by the end of September, substantially improving its financial flexibility and positioning for future…
Generate Biomedicines Inc., a Nasdaq-listed clinical-stage generative biology company, announced its management team's participation in several key September 2026 investor conferences. The company highlights its innovative platform that merges machine learning and biological engineering to develop novel therapeutics targeting difficult-to-drug prot…
Lantronix Inc., a leader in Edge AI and Industrial IoT solutions, announced that CEO Saleel Awsare will participate in several upcoming investor and industry events focused on government, defense technology, aerospace, and unmanned systems. These appearances aim to highlight Lantronix's capabilities in NDAA-compliant unmanned systems and critical i…
Zenas BioPharma announced a virtual investor event to discuss Obexelimab, its lead drug candidate for treating Immunoglobulin G4-Related Disease (IgG4-RD). The event will cover disease overview, treatment landscape, and the company's commercial strategies ahead of potential FDA approval. The FDA has accepted Zenas' Biologics License Application for…
Microchip Technology has announced the SY757xx family of low-voltage 1.2V LVCMOS clock buffers designed to simplify system design in advanced electronics such as FPGAs and SoCs, which use advanced FinFET process nodes. These devices eliminate the need for discrete components, reduce board complexity, and provide ultra-low additive jitter performanc…
IREN Limited announced that its 2GW Sweetwater Hub, consisting of Sweetwater 1 (1,400MW) and Sweetwater 2 (600MW), has been conditionally included as base load in the ERCOT Batch Zero process. This inclusion supports the development of over 5GW of global AI cloud data center capacity. Construction of Sweetwater 1 data center capacity is underway wi…
Invivyd, Inc., a biopharmaceutical company focused on viral infectious diseases, announced management's participation in three prominent September 2026 investor conferences including Citi’s Biopharma Back to School, Cantor Global Healthcare, and H.C. Wainwright Annual Global Investment Conferences, featuring fireside chats and investor meetings. Th…
Daniel Masters, Co-Founder and Non-Executive Director of CoinShares PLC, has adopted a Rule 10b5-1 trading plan to sell up to approximately 3.6% of shares outstanding via scheduled transactions through December 31, 2027. Most sales relate to unwinding a 2023-2024 financing arrangement, with a limited reduction in his beneficial ownership to about 1…
NovaBridge Biosciences, a Nasdaq-listed global biotechnology company focused on oncology and ophthalmology therapeutic programs, announced the appointment of Martin Dewhurst to its Board of Directors as an independent director. Dewhurst brings over 30 years of leadership and governance experience in healthcare, serving on multiple boards globally a…
Editas Medicine has appointed Dan Ory, M.D., an experienced biotechnology and cardiovascular medicine executive, as Chief Medical Officer. Dr. Ory will oversee clinical development strategy, particularly as the company prepares to advance EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia, towards clinical trials. His expertise in…
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on CNS disorder treatments, announced management participation in three upcoming investor conferences in September 2026. The Company develops NMDA platform-based therapeutics for conditions including suicidal depression, chronic pain, and PTSD, with notable FDA designations fo…
X4 Pharmaceuticals announced a positive outcome from its FDA Type C meeting, with the FDA agreeing to reduce the sample size of its global 4WARD Phase 3 trial for mavorixafor treating chronic neutropenia from 176 to 126 participants. This reduction maintains adequate statistical power for key endpoints and a sufficient safety database, allowing fas…
Beamr Imaging Ltd. has joined the VAST Cosmos Partner Program and collaborated with VAST Data and NVIDIA to deliver AI-powered video enhancement workflows aimed at broadcasters and content owners. Their solution enables upscaling and AI enhancement of lower-resolution video archives while optimizing storage and delivery costs, supporting monetizati…
Nkarta, Inc. announced selection of three presentations at the ACR Convergence 2026 showcasing preliminary safety and clinical activity data for their NKX019 allogeneic CAR-NK cell therapy in autoimmune diseases. The presentations highlight promising safety profiles and initial efficacy signals in idiopathic inflammatory myopathy and systemic scler…
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focusing on therapies for neuropathic corneal pain and anterior segment eye diseases, announced its participation in the Cantor Global Healthcare Conference. The event follows recent positive FDA Type D meeting feedback validating OKYO's regulatory and clinical pathway for its lead dru…
Tilray Brands' craft beer subsidiary BrewDog has announced a five-year exclusive official beer partnership with Leicester Tigers, one of England’s premier rugby union clubs. Starting from the 2026-27 season, BrewDog will provide a full lineup of its beers at Leicester’s Welford Road Stadium, launching a new Tigers-branded ale and fan activations to…
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company focused on oral antiviral therapies, announced its presentation at the Morgan Stanley Global Healthcare Conference. The company will discuss its late-stage development programs including a Phase 3 regimen for hepatitis C and Phase 1 development for hepatitis E treatments.
Erasca, Inc., a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. Management will engage in a fireside chat and one-on-one investor meetings. The event highlights the company's ongoing commitment to developing innovative c…
CalciMedica, a clinical-stage biopharmaceutical company focusing on CRAC channel inhibitors for inflammatory and cardiopulmonary diseases, announced its management will present and hold investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company is developing two main compounds: Auxora for in…
